India Approves First Dengue Vaccine ‘QDENGA’: A Historic Step Towards Dengue Control
The Drug Controller General of India (DCGI) has approved the use of 'QDENGA,' the first dengue vaccine, developed by Japan's Takeda Biopharmaceuticals. It is a live-attenuated vaccine approved for the 4–60 age group; it offers protection against all four serotypes of the dengue virus and does not require prior screening. Given the absence of specific antiviral drugs for dengue, this vaccine is considered a significant milestone for dengue control and public health in India. Pre-qualified by the WHO and approved in 43 countries, the vaccine has demonstrated efficacy in clinical trials, reducing the risk of dengue infection by approximately 80% and the risk of hospitalization by over 90%.
The Drug Controller General of India (DCGI) has granted approval for the use of ‘QDENGA,’ the first dengue vaccine. This vaccine has been developed by Japan's Takeda Biopharmaceuticals. It is the first approved vaccine available in India for dengue prevention and can be administered to individuals in the 4–60 age group.
Key Features of QDENGA
QDENGA is a live-attenuated vaccine that provides protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). Two doses of the vaccine are administered at a prescribed interval. A notable feature is that prior screening (serological screening) for dengue infection is not required before vaccination, making it easier to conduct large-scale vaccination campaigns.
Significance for Dengue Control
In India, dengue is a major viral disease transmitted by the Aedes aegypti mosquito, and the number of cases has risen significantly over the past two decades. As there is currently no specific antiviral medication for dengue, a combination of vaccination, mosquito control, disease surveillance, and public awareness forms the core strategy for its prevention. The approval of Qdenga is considered a significant public health milestone in dengue control.
Efficacy and Global Status
The efficacy of Qdenga has been demonstrated in numerous international studies, including the global TIDES Phase-III clinical trial. Trials showed it to be approximately 80% effective against laboratory-confirmed dengue infections and capable of reducing the risk of hospitalization by more than 90%. The vaccine has received World Health Organization (WHO) Prequalification and has been approved for use in 43 countries.
Significance for UPSC
Questions related to dengue, the Aedes mosquito, the four serotypes of the dengue virus, the DCGI, WHO Prequalification, live-attenuated vaccines, and public health programs may be asked in the UPSC Preliminary Examination. This topic is also important for the Main Examination (GS Paper-III) in the context of vaccine development, biotechnology, infectious disease control, epidemic management, and India's public health policy.
